RxDoctor Payments Data

Michael Ondich, DO

Family Medicine · Kittanning, PANPI 1871587394

Payments from drug & device makers

$3,201in general payments, 2019–2025

Across 199 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$987
  • GSK$641
  • Boehringer Ingelheim$348
  • Lilly USA, LLC$234
  • Merck$225
  • Pfizer$202
  • plus $565 from 12 others

What the payments were for

  • Food & beverage$3,186100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,201 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$5,409
Medicare patients
34
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin139$109,878
OzempicSemaglutide47$48,812
EliquisApixaban42$30,287
JanuviaSitagliptin Phosphate30$26,277
TrulicityDulaglutide19$19,240
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,963
RybelsusSemaglutide18$16,917
XareltoRivaroxaban11$14,034
TradjentaLinagliptin15$9,771
Spiriva RespimatTiotropium Bromide19$9,602
Tresiba Flextouch U-200Insulin Degludec12$7,201
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$6,300
Enalapril Maleate182$4,733
Lantus SolostarInsulin Glargine,hum.Rec.Anlog46$3,945
Atorvastatin Calcium293$3,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$348$129,250173 claims
Novo NordiskOzempic, Rybelsus$987$65,72965 claims
PfizerEliquis$202$30,28742 claims
MerckJanuvia$225$26,27730 claims
Lilly USA, LLCTrulicity$234$19,24019 claims
GSKTrelegy Ellipta$641$16,96319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Kittanning

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →